Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Behcet Syndrome D001528 7 associated lipids
Infant, Premature, Diseases D007235 7 associated lipids
Mucositis D052016 7 associated lipids
Bronchiectasis D001987 7 associated lipids
Agranulocytosis D000380 7 associated lipids
Pneumococcal Infections D011008 7 associated lipids
Rheumatic Diseases D012216 7 associated lipids
Pelvic Pain D017699 7 associated lipids
Coronary Thrombosis D003328 7 associated lipids
Ear Diseases D004427 7 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Rhinitis, Allergic, Seasonal D006255 7 associated lipids
Klebsiella Infections D007710 7 associated lipids
Coronary Stenosis D023921 6 associated lipids
Xeroderma Pigmentosum D014983 6 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Blood Loss, Surgical D016063 6 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Sneezing D012912 6 associated lipids
Thrombophilia D019851 6 associated lipids
Gliosis D005911 6 associated lipids
Heart Injuries D006335 6 associated lipids
Glomerulonephritis, Membranous D015433 6 associated lipids
Intestinal Obstruction D007415 6 associated lipids
Osteonecrosis D010020 5 associated lipids
Spasm D013035 5 associated lipids
Colonic Diseases D003108 5 associated lipids
Shock, Cardiogenic D012770 5 associated lipids
Strongylida Infections D017206 5 associated lipids
Neoplastic Cells, Circulating D009360 5 associated lipids
Liver Failure D017093 5 associated lipids
Hepatitis, Alcoholic D006519 5 associated lipids
Granulomatosis with Polyangiitis D014890 5 associated lipids
Hyperuricemia D033461 4 associated lipids
Bronchopulmonary Dysplasia D001997 4 associated lipids
Viremia D014766 4 associated lipids
AIDS Dementia Complex D015526 4 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Burns, Inhalation D002059 4 associated lipids
Shock, Traumatic D012774 4 associated lipids
Hypertrophy, Right Ventricular D017380 4 associated lipids
Brain Injuries D001930 4 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Milk Hypersensitivity D016269 4 associated lipids
Thrombocytosis D013922 4 associated lipids
Cluster Headache D003027 4 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Thrombasthenia D013915 4 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Wang KS et al. Protective effects of a PAF antagonist against liver injury induced by warm ischemia or cold preservation. 1992 Transplant. Proc. pmid:1496669
Takada Y et al. Improvement of allograft viability with organs procured from non-heart-beating donors in porcine liver transplantation. 2000 Transplant. Proc. pmid:10715416
Peyman JA et al. HLA-DR genes are silenced in human trophoblasts and stimulation of signal transduction pathways does not circumvent interferon-gamma unresponsiveness. 1992 Transplant. Proc. pmid:1533073
Taniguchi S et al. Effects of a platelet-activating factor antagonist at different doses given simultaneously with double-filtration plasmapheresis on cardiac xenograft survival. 1994 Transplant. Proc. pmid:8171719
Takada Y et al. Energy metabolism of hepatic allografts subjected to prolonged warm ischemia and pharmacologic modulation with FK506 and platelet activating factor antagonist. 1998 Transplant. Proc. pmid:9838621
Fukunaga K et al. Successful liver transplantation from non-heart-beating donors by blockade of endothelin and PAE. 1998 Transplant. Proc. pmid:9838664
Lloberas N et al. The ether phospholipids trail: blood timing in renal ischemia-reperfusion injury. 2002 Transplant. Proc. pmid:11959179
Castellvi J et al. Effect of the platelet-activating factor antagonist BN-52021 on liver preservation (4 degrees): experimental study in isolated reperfused rat liver model. 2002 Transplant. Proc. pmid:11959181
Keskinoglu A et al. Inflammatory lipid mediators and immunologic recognition in allogeneic renal transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9122948
Otte KE et al. Xenoperfusion of rabbit kidney and the impact of BN 52021: a specific antagonist of platelet-activating factor. 1990 Transplant. Proc. pmid:2349668
Moreno P et al. Changes in peripheral blood levels of platelet-activating factor after orthotopic liver transplantation. 1993 Transplant. Proc. pmid:8395105
Kecskemeti V and Balogh I Cardiac electrophysiologic and ultrastructural effects of platelet-activating factor and its antagonist BN 52021. 1995 Transplant. Proc. pmid:7482928
Yin M et al. Platelet-activating factor antagonist TCV-309 protects rat kidneys against ischemia-reperfusion injury. 1995 Transplant. Proc. pmid:7482939
Spiegel HU et al. Beneficial effect of the platelet-activating factor antagonist WEB 2170 on reperfusion injury after orthotopic liver transplantation. 1995 Transplant. Proc. pmid:7482955
Mahmoud FF et al. In vitro effects of ginkgolide B combined with cyclosporin A on T-lymphocyte activation and IL-5 expression in peripheral blood mononuclear cells from asthmatic subjects. 2002 Transplant. Proc. pmid:12431672
Iwamoto H et al. Beneficial effect of machine perfusion preservation on liver transplantation from non-heart-beating donors. 2000 Transplant. Proc. pmid:11119873
Da Costa M et al. Prolongation of rat heart allograft survival using low-dose cyclosporine and PAF antagonist WEB 2170. 1990 Transplant. Proc. pmid:2389490
Bergmann R et al. Effects of a PAF-antagonist (WEB 2086) on hyperacute xenogeneic rejection in ex vivo perfused kidneys. 1990 Transplant. Proc. pmid:2389511
Immunomodulation: other approaches. 1988 Transplant. Proc. pmid:3347955
Renkonen R et al. Second messenger pathways in lymphocyte binding and penetration through graft vascular endothelium. 1991 Transplant. Proc. pmid:1846709
O'Hair DP et al. Platelet activating factor antagonist RP-59227 reduces vascular injury in discordant cardiac xenograft rejection. 1992 Transplant. Proc. pmid:1566490
Pignol B et al. Potentiation of immunosuppressive action of cyclosporine A by platelet-activating factor antagonists: an approach of the mechanism of action of these drugs in the prevention of graft rejection. 1988 Transplant. Proc. pmid:3259039
First International Alexis Carrel Conference on Lipid Mediators in Organ Transplantation. April 8-10, 1986, Washington, DC. 1986 Transplant. Proc. pmid:3765055
Hirt SW et al. Antagonisation of platelet activating factor--a new therapeutic concept for improvement of organ quality in lung preservation. 1992 Transpl. Int. pmid:14621825
Torras J et al. Protective effect of the PAF antagonist BN 52021 in an experimental renal warm ischemia model. 1993 Transpl. Int. pmid:8347271
Räisänen A et al. Effect of platelet-activating factor (PAF) receptor blockers on smooth muscle cell replication in vitro and allograft arteriosclerosis in vivo. 1993 Transpl. Int. pmid:8216700
Shukla SD et al. Response to platelet-activating factor in human platelets stored and aged in plasma. Decrease in aggregation, phosphoinositide turnover, and receptor affinity. 1989 Jul-Aug Transfusion pmid:2546298
Guerrant RL et al. Diarrhea, demography and cell signaling: lessons from microbial toxins. 1997 Trans. Am. Clin. Climatol. Assoc. pmid:9108674
Melo RC et al. Intragranular vesiculotubular compartments are involved in piecemeal degranulation by activated human eosinophils. 2005 Traffic pmid:16138901
Gambero A et al. Signalling pathways regulating human neutrophil migration induced by secretory phospholipases A2. 2004 Toxicon pmid:15450921
Teixeira CF et al. Hyperalgesia induced by Bothrops jararaca venom in rats: role of eicosanoids and platelet activating factor (PAF). 1994 Toxicon pmid:8052996
Shiroma N et al. Haemodynamic and haematologic effects of Acanthaster planci venom in dogs. 1994 Toxicon pmid:7846692
Havt A et al. The renal effects of Bothrops jararacussu venom and the role of PLA(2) and PAF blockers. 2001 Toxicon pmid:11600146
Castro-Faria-Neto HC et al. Pro-inflammatory activity of enterolobin: a haemolytic protein purified from seeds of the Brazilian tree Enterolobium contortisiliquum. 1991 Toxicon pmid:1796477
Yara A et al. Cardiovascular effects of Acanthaster planci venom in the rat: possible involvement of PAF in its hypotensive effect. 1992 Toxicon pmid:1440631
Rees RS et al. Plasma components are required for platelet activation by the toxin of Loxosceles reclusa. 1988 Toxicon pmid:3245050
Freire-Maia L and de Matos IM Heparin or a PAF antagonist (BN-52021) prevents the acute pulmonary edema induced by Tityus serrulatus scorpion venom in the rat. 1993 Toxicon pmid:8266352
Tai H et al. TMVA, a snake C-type lectin-like protein from Trimeresurus mucrosquamatus venom, activates platelet via GPIb. 2004 Toxicon pmid:15501291
Grandoni KM et al. Trichothecene mycotoxins inhibit phosphoinositide hydrolysis in bovine platelets stimulated with platelet activating factor. 1992 Toxicology pmid:1311467
Pearson JM et al. Neither platelet activating factor nor leukotrienes are critical mediators of liver injury after lipopolysaccharide administration. 1997 Toxicology pmid:9231696
Flaherty MM et al. Nonclinical evaluation of GMA161--an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. 2012 Toxicol. Sci. pmid:22025730
Feuerstein G et al. Protective effect of a PAF-acether antagonist, BN 52021, in trichothecene toxicosis. 1987 Toxicol. Lett. pmid:3660430
Bailie MB et al. Platelet activating factor receptor blockade alone or in combination with leukotriene synthesis inhibition does not ameliorate alpha-naphthylisothiocyanate-induced hepatotoxicity. 1996 Toxicol. Lett. pmid:8614909
Mahgoub AA Thymoquinone protects against experimental colitis in rats. 2003 Toxicol. Lett. pmid:12749817
Baskin SI et al. The effects of EDRF/NO releasers or calcium ionophore A23187 on cyanide toxicity in mice. 1996 Toxicol. Appl. Pharmacol. pmid:8806852
Wright DT et al. Ozone stimulates release of platelet activating factor and activates phospholipases in guinea pig tracheal epithelial cells in primary culture. 1994 Toxicol. Appl. Pharmacol. pmid:8048050
Nomura DK et al. Dual roles of brain serine hydrolase KIAA1363 in ether lipid metabolism and organophosphate detoxification. 2008 Toxicol. Appl. Pharmacol. pmid:18164358
Samet JM and Friedman M Effect of ozone on platelet activating factor metabolism in phorbol-differentiated HL60 cells. 1992 Toxicol. Appl. Pharmacol. pmid:1440609
Hanslik T et al. Effect of the platelet activating factor antagonist BN52021 in rabbits: role in gentamicin nephrotoxicity. 1994 Toxicol. Appl. Pharmacol. pmid:8079343
Ramos G et al. Platelet activating factor receptor binding plays a critical role in jet fuel-induced immune suppression. 2004 Toxicol. Appl. Pharmacol. pmid:15020195